Osteoporosis, Age-Related

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
Persistence With Prolia® (Denosumab) in Postmenopausal Women With OsteoporosisN/A1 trial
Active Trials
NCT02732210Completed935Est. Apr 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenPersistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

Clinical Trials (1)

Total enrollment: 935 patients across 1 trials

NCT02732210AmgenPersistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

Start: Jul 2011Est. completion: Apr 2014935 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space